GALMED ANNOUNCES THE BREAKTHROUGH DEVELOPMENT OF NOVEL LNP CARDIAC TARGETED FORMULATION OF ITS SCD1 INHIBITOR, ARAMCHOL

Reuters · 1d ago

Please log in to view news